As of 2024-07-27, the Relative Valuation of Alnylam Pharmaceuticals Inc (ALNY) is (45.21) USD. This relative valuation is based on P/E multiples. With the latest stock price at 234.84 USD, the upside of Alnylam Pharmaceuticals Inc based on Relative Valuation is -119.3%.
The range of the Relative Valuation is (40.89) - (49.92) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 15.6x - 19.4x | 17.5x |
| Forward P/E multiples | 14.9x - 19.0x | 17.0x |
| Fair Price | (40.89) - (49.92) | (45.21) |
| Upside | -117.4% - -121.3% | -119.3% |
| Date | P/E |
| 2024-07-26 | -89.47 |
| 2024-07-25 | -90.63 |
| 2024-07-24 | -90.10 |
| 2024-07-23 | -89.26 |
| 2024-07-22 | -89.76 |
| 2024-07-19 | -90.61 |
| 2024-07-18 | -90.18 |
| 2024-07-17 | -91.44 |
| 2024-07-16 | -95.18 |
| 2024-07-15 | -97.60 |
| 2024-07-12 | -99.25 |
| 2024-07-11 | -99.45 |
| 2024-07-10 | -98.20 |
| 2024-07-09 | -97.05 |
| 2024-07-08 | -97.19 |
| 2024-07-05 | -95.64 |
| 2024-07-03 | -94.74 |
| 2024-07-02 | -94.34 |
| 2024-07-01 | -92.70 |
| 2024-06-28 | -92.58 |
| 2024-06-27 | -94.10 |
| 2024-06-26 | -93.41 |
| 2024-06-25 | -91.49 |
| 2024-06-24 | -84.92 |
| 2024-06-21 | -63.13 |
| 2024-06-20 | -59.97 |
| 2024-06-18 | -58.62 |
| 2024-06-17 | -59.93 |
| 2024-06-14 | -61.11 |
| 2024-06-13 | -60.98 |
| 2024-06-12 | -60.59 |
| 2024-06-11 | -59.60 |
| 2024-06-10 | -58.47 |
| 2024-06-07 | -58.21 |
| 2024-06-06 | -56.88 |
| 2024-06-05 | -57.93 |
| 2024-06-04 | -57.06 |
| 2024-06-03 | -57.32 |
| 2024-05-31 | -56.55 |
| 2024-05-30 | -57.16 |
| 2024-05-29 | -55.98 |
| 2024-05-28 | -57.17 |
| 2024-05-24 | -56.29 |
| 2024-05-23 | -56.91 |
| 2024-05-22 | -57.49 |
| 2024-05-21 | -57.00 |
| 2024-05-20 | -57.24 |
| 2024-05-17 | -56.92 |
| 2024-05-16 | -57.61 |
| 2024-05-15 | -56.16 |